Morepen shares surge 15% on ₹825 crore multi-year global CDMO deal

Morepen Laboratories secures a ₹825 crore CDMO mandate from a global pharmaceutical company, boosting shares by 14.58 percent. Supplies start in four to five months, marking a major milestone.

Leave a Reply

Your email address will not be published. Required fields are marked *